1. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Issue 2 (February 2022) Authors: Schjesvold, Fredrik H; Dimopoulos, Meletios-Athanasios; Delimpasi, Sosana; Robak, Pawel; Coriu, Daniel; Legiec, Wojciech; Pour, Luděk; Špička, Ivan; Masszi, Tamas; Doronin, Vadim; Minarik, Jiri; Salogub, Galina; Alekseeva, Yulia; Lazzaro, Antonio; Maisnar, Vladimir; Mikala, Gábor; Rosiñol, Laura;... Journal: Lancet Issue: Volume 9:Issue 2(2022) Page Start: e98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Issue 10262 (14th November 2020) Authors: Grosicki, Sebastian; Simonova, Maryana; Spicka, Ivan; Pour, Ludek; Kriachok, Iryrna; Gavriatopoulou, Maria; Pylypenko, Halyna; Auner, Holger W; Leleu, Xavier; Doronin, Vadim; Usenko, Ganna; Bahlis, Nizar J; Hajek, Roman; Benjamin, Reuben; Dolai, Tuphan K; Sinha, Dinesh K; Venner, Christopher P; G... Journal: Lancet Issue: Volume 396:Issue 10262(2020) Page Start: 1563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗